
Renalytix AI plc RNLX
Quarterly report 2025-Q1
added 05-23-2026
Renalytix AI plc Operating Income 2011-2026 | RNLX
Operating profit (also called operating income or profit from core activities) is a financial metric that reflects a company's profit from its main operational activities before interest expenses and taxes are taken into account.
FormulaOperating profit = Revenue – Operating expensesFeatures of the metric
- Evaluates business efficiency
Shows how well the company controls its production and administrative costs. - Independent of financial structure
Excludes the impact of debt burden (interest) and taxes, allowing objective comparison of companies. - Main source for growth
High operating profit provides resources for investments, business expansion, and increased competitiveness.
If a company shows strong operating profit, it signals to investors that the core business is operating efficiently, even if net profit is temporarily reduced due to debt or tax burden.
Annual Operating Income Renalytix AI plc
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -29.6 M | -42.2 M | -53.2 M | -31.9 M | -10.3 M | -42.3 M | -567 K | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -567 K | -53.2 M | -30 M |
Quarterly Operating Income Renalytix AI plc
| 2025-Q1 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -4.09 M | -6.55 M | -8.64 M | -8.89 M | -8.64 M | -8.89 M | - | -10.9 M | -9.65 M | -11.7 M | -53.2 M | -14.5 M | -13.8 M | -11.8 M | -31.9 M | -8.07 M | -8.61 M | - | -10.3 M | - | - | - | -42.3 M | - | - | - | -567 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| -567 K | -53.2 M | -14.4 M |
Operating Income of other stocks in the Diagnostics research industry
| Issuer | Operating Income | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Enzo Biochem
ENZ
|
-12.4 M | - | -8.98 % | $ 14.8 K | ||
|
Centogene N.V.
CNTG
|
-46 M | - | -6.23 % | $ 30.6 M | ||
|
Heska Corporation
HSKA
|
-20.3 M | - | - | $ 1.31 B | ||
|
Quest Diagnostics Incorporated
DGX
|
1.56 B | $ 206.0 | 0.73 % | $ 22.9 B | ||
|
Celcuity
CELC
|
-172 M | $ 95.97 | 3.65 % | $ 4.49 B | ||
|
Akumin
AKU
|
-28.1 M | - | -17.87 % | $ 25.9 M | ||
|
Co-Diagnostics
CODX
|
-50.2 M | $ 4.46 | -0.89 % | $ 5.93 M | ||
|
Fulgent Genetics
FLGT
|
-91.1 M | $ 18.75 | 1.32 % | $ 577 M | ||
|
Castle Biosciences
CSTL
|
-42.8 M | $ 21.44 | 1.68 % | $ 621 M | ||
|
Aspira Women's Health
AWH
|
-7.91 M | - | -6.19 % | $ 10.5 M | ||
|
Accelerate Diagnostics
AXDX
|
-35.3 M | - | -61.36 % | $ 2.46 M | ||
|
Biocept
BIOC
|
-32 M | - | -13.05 % | $ 7.29 M | ||
|
ICON Public Limited Company
ICLR
|
443 M | $ 153.61 | 1.18 % | $ 12 B | ||
|
Guardant Health
GH
|
-437 M | $ 132.08 | 1.5 % | $ 16.6 B | ||
|
Illumina
ILMN
|
807 M | $ 165.22 | 3.24 % | $ 25.6 B | ||
|
CareDx, Inc
CDNA
|
-30.8 M | $ 23.03 | 1.21 % | $ 1.23 B | ||
|
Chembio Diagnostics
CEMI
|
-23.6 M | - | 0.22 % | $ 16.8 M | ||
|
Check-Cap Ltd.
CHEK
|
-2.37 M | - | - | $ 9.42 M | ||
|
Interpace Biosciences
IDXG
|
4.08 M | $ 1.74 | 3.57 % | $ 7.7 M | ||
|
HTG Molecular Diagnostics
HTGM
|
-20.8 M | - | -20.0 % | $ 1.06 M | ||
|
Global Cord Blood Corporation
CO
|
609 M | - | - | $ 399 M | ||
|
Genetron Holdings Limited
GTH
|
-702 M | - | 0.12 % | $ 80.1 M | ||
|
NeoGenomics
NEO
|
-116 M | $ 11.61 | 1.49 % | $ 1.49 B | ||
|
National Research Corporation
NRC
|
22.6 M | $ 20.24 | 2.48 % | $ 453 M | ||
|
DermTech
DMTK
|
-104 M | - | -11.32 % | $ 2.94 M | ||
|
Lantheus Holdings
LNTH
|
311 M | $ 100.09 | 0.11 % | $ 6.75 B | ||
|
Charles River Laboratories International
CRL
|
25.2 M | $ 188.96 | -0.55 % | $ 9.37 B | ||
|
Pacific Biosciences of California
PACB
|
-554 M | $ 1.41 | 2.55 % | $ 423 M | ||
|
Medpace Holdings
MEDP
|
535 M | $ 465.31 | -0.32 % | $ 13.4 B | ||
|
Exact Sciences Corporation
EXAS
|
-206 M | - | - | $ 19.8 B | ||
|
Myriad Genetics
MYGN
|
-387 M | $ 4.78 | 5.29 % | $ 443 M | ||
|
Natera
NTRA
|
-310 M | $ 223.42 | 0.27 % | $ 30.5 B | ||
|
Personalis
PSNL
|
-88.1 M | $ 10.11 | 3.64 % | $ 902 M | ||
|
Koninklijke Philips N.V.
PHG
|
1.42 B | $ 26.03 | -1.77 % | $ 24.7 B | ||
|
Senseonics Holdings
SENS
|
-68.3 M | $ 7.54 | 1.41 % | $ 315 M | ||
|
QIAGEN N.V.
QGEN
|
466 M | - | - | $ 10.6 B | ||
|
Soleno Therapeutics
SLNO
|
9.41 M | - | - | $ 2.69 B | ||
|
Biomerica
BMRA
|
-5.14 M | $ 2.03 | -1.02 % | $ 4.66 M | ||
|
Twist Bioscience Corporation
TWST
|
-136 M | $ 71.38 | 1.88 % | $ 4.27 B | ||
|
Laboratory Corporation of America Holdings
LH
|
1.38 B | $ 272.06 | 0.32 % | $ 22.6 B | ||
|
Thermo Fisher Scientific
TMO
|
7.75 B | $ 490.53 | -0.77 % | $ 185 B | ||
|
Trinity Biotech plc
TRIB
|
-21.2 M | $ 0.67 | 0.87 % | $ 241 M | ||
|
Motus GI Holdings
MOTS
|
-11.9 M | - | -34.28 % | $ 263 K | ||
|
Neogen Corporation
NEOG
|
-1.06 B | $ 9.35 | 0.65 % | $ 2.03 B | ||
|
Waters Corporation
WAT
|
271 M | $ 371.06 | -0.02 % | $ 22.1 B |